Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan

Anne M S Belonje, B. Daan Westenbrink, Adriaan A. Voors, Stephan von Haehling, Pjotr Ponikowski, Stefan D. Anker, Dirk J. van Veldhuisen, Kenneth Dickstein

Research output: Contribution to journalArticle

Abstract

Background: In patients with chronic heart failure, erythropoietin (Epo) levels are increased and related to a poor prognosis. Furthermore, Epo levels in these patients show a weak correlation with hemoglobin levels. Methods: This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial in which serum Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients with an acute myocardial infarction complicated by signs or symptoms of heart failure. We investigated the determinants and the prognostic role of elevated Epo levels in these patients, and we studied the change in Epo levels by either captopril or losartan. Results: The correlation between Epo and hemoglobin at baseline (r = 0.348, P <.001) and after 1 month (r = 0.272, P 

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalAmerican Heart Journal
Volume157
Issue number1
DOIs
Publication statusPublished - Jan 2009

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Belonje, A. M. S., Westenbrink, B. D., Voors, A. A., Haehling, S. V., Ponikowski, P., Anker, S. D., van Veldhuisen, D. J., & Dickstein, K. (2009). Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. American Heart Journal, 157(1), 91-96. https://doi.org/10.1016/j.ahj.2008.08.020